Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial

Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial

Abstract Aumolertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is widely utilized for advanced EGFR-mutant non-small cell lung cancer patients (NSCLCm). This single-arm, phase II trial (NCT04685070) assessed the feasibility of neoadjuvant Aumolertini...

Full description

Saved in:
Bibliographic Details
Main Authors: Dongliang Bian, Shuyu Ji, Yue Liu, Zhida Huang, Lei Jiang, Ming Liu, Xiao Bao, Jie Yang, Yirui Zhou, Junjie Hu, Liangdong Sun, Yingzhi Zheng, Jie Huang, Jing Liu, Xinsheng Zhu, Jing Zhang, Lele Zhang, Xiaogang Liu, Wenxin He, Dong Xie, Yuming Zhu, Chunyan Wu, Deping Zhao, Liang Duan, Gening Jiang, Peng Zhang
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-58435-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-58435-9

Similar Items